KR20050075356A - 화합물, 조성물 및 방법 - Google Patents

화합물, 조성물 및 방법 Download PDF

Info

Publication number
KR20050075356A
KR20050075356A KR1020057006260A KR20057006260A KR20050075356A KR 20050075356 A KR20050075356 A KR 20050075356A KR 1020057006260 A KR1020057006260 A KR 1020057006260A KR 20057006260 A KR20057006260 A KR 20057006260A KR 20050075356 A KR20050075356 A KR 20050075356A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
hydrogen
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057006260A
Other languages
English (en)
Korean (ko)
Inventor
지앙핑 퀴안
구스타브 베르그네스
데이빗 제이 주니어 모건스
스티븐 데이빗 나이트
다쉬언트 다낙
Original Assignee
싸이토키네틱스, 인코포레이티드
스미스 클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이토키네틱스, 인코포레이티드, 스미스 클라인 비참 코포레이션 filed Critical 싸이토키네틱스, 인코포레이티드
Publication of KR20050075356A publication Critical patent/KR20050075356A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057006260A 2002-10-11 2003-10-02 화합물, 조성물 및 방법 Withdrawn KR20050075356A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41788902P 2002-10-11 2002-10-11
US60/417,889 2002-10-11

Publications (1)

Publication Number Publication Date
KR20050075356A true KR20050075356A (ko) 2005-07-20

Family

ID=32094113

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057006260A Withdrawn KR20050075356A (ko) 2002-10-11 2003-10-02 화합물, 조성물 및 방법

Country Status (19)

Country Link
US (1) US7476743B2 (https=)
EP (1) EP1558588A4 (https=)
JP (1) JP2006502219A (https=)
KR (1) KR20050075356A (https=)
CN (1) CN1726198A (https=)
AR (1) AR044193A1 (https=)
AU (1) AU2003282665A1 (https=)
BR (1) BR0315247A (https=)
CA (1) CA2501938A1 (https=)
IL (1) IL167936A0 (https=)
IS (1) IS7798A (https=)
MX (1) MXPA05003830A (https=)
NO (1) NO20052267L (https=)
NZ (1) NZ539643A (https=)
PL (1) PL375889A1 (https=)
RU (1) RU2005114491A (https=)
TW (1) TW200418818A (https=)
WO (1) WO2004032840A2 (https=)
ZA (1) ZA200503733B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
JP5343363B2 (ja) * 2008-01-31 2013-11-13 アイシン精機株式会社 シートクッション調整装置
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
JP2013523867A (ja) 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物
WO2012095691A1 (en) * 2011-01-15 2012-07-19 Jubilant Life Sciences Ltd. An improved process for producing aminopyridines
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
US20250215039A1 (en) * 2022-03-30 2025-07-03 Primefour Therapeutics, Inc. Nucleosides for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793532A (fr) * 1971-12-29 1973-06-29 Upjohn Co Nouvelles 1,2,4-triazol-3-ones et leur preparation
US3748339A (en) * 1972-05-05 1973-07-24 Upjohn Co 2-(3-(1-(dimethylamino)alkyl)-1,5-dihydro-5-oxo - 1 - substituted-4h-1,2,4-triazol-4-yl)benzophenone and process
IT1068010B (it) * 1976-11-17 1985-03-21 Montedison Spa Nuovi esteri fosforici derivati dall' 1-2-4 triazolo ad azione insetticida,nematocida e acaricida e loro preparazione
NL7712430A (nl) * 1976-11-17 1978-05-19 Montedison Spa Nieuwe fosforzuuresters, afgeleid van 1.2.4- -triazool, met een insecticide, nematocide en acaricide werking en werkwijze ter bereiding daarvan.
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB9211193D0 (en) * 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
AU722883B2 (en) * 1995-10-18 2000-08-10 Merck & Co., Inc. Cyclopentyl tachykinin receptor antagonists
JP2002234874A (ja) * 2000-09-26 2002-08-23 Tanabe Seiyaku Co Ltd ５−フェニルベンジルアミン誘導体、その製法及びその合成中間体
WO2002034699A2 (en) * 2000-10-26 2002-05-02 Merck & Co., Inc. Mammalian metabolites of a tachykinin receptor antagonist
MXPA04012642A (es) * 2002-06-14 2005-03-23 Merck & Co Inc Inhibidores de la cinesina mitotica.

Also Published As

Publication number Publication date
MXPA05003830A (es) 2005-06-23
PL375889A1 (en) 2005-12-12
NO20052267L (no) 2005-05-31
AR044193A1 (es) 2005-09-07
AU2003282665A1 (en) 2004-05-04
EP1558588A4 (en) 2006-11-02
EP1558588A2 (en) 2005-08-03
TW200418818A (en) 2004-10-01
CN1726198A (zh) 2006-01-25
RU2005114491A (ru) 2006-02-10
ZA200503733B (en) 2006-02-22
NZ539643A (en) 2006-11-30
US20060189671A1 (en) 2006-08-24
IL167936A0 (en) 2009-02-11
CA2501938A1 (en) 2004-04-22
WO2004032840A2 (en) 2004-04-22
US7476743B2 (en) 2009-01-13
BR0315247A (pt) 2005-08-30
JP2006502219A (ja) 2006-01-19
WO2004032840A3 (en) 2004-10-14
IS7798A (is) 2005-04-11

Similar Documents

Publication Publication Date Title
KR20050036911A (ko) 화합물들, 방법 및 조성물
US20040082567A1 (en) Compounds, compositions, and methods
EP1692112A1 (en) Compounds, compositions, and methods
EP1553931A1 (en) Compounds, compositions, and methods
WO2004064741A2 (en) Compounds, compositions, and methods
EP1539727B1 (en) Compounds, compositions, and methods for treating cellular proliferative diseases
KR20050075356A (ko) 화합물, 조성물 및 방법
US20080312310A1 (en) Compounds, Compositions and Methods
US20080021079A1 (en) Compounds, Compositions, and Methods
US7271167B2 (en) Compounds, compositions, and methods
US20050197327A1 (en) Compounds, compositions, and methods
US20070032536A1 (en) Compounds, compositions and methods
EP1622883A2 (en) Compounds, compositions, and methods
US20070066591A1 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050411

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid